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Abstract
In the event of a novel influenza A virus pandemic, prophylaxis mediated by antibodies provides an adjunct control option
to vaccines and antivirals. This strategy is particularly pertinent to unvaccinated populations at risk during the lag time to
produce and distribute an effective vaccine. Therefore, development of effective prophylactic therapies is of high
importance. Although previous approaches have used systemic delivery of monoclonal antibodies or convalescent sera,
available supply is a serious limitation. Here, we have investigated intranasal delivery of influenza-specific ovine polyclonal
IgG antibodies for their efficacy against homologous influenza virus challenge in a mouse model. Both influenza-specific IgG
and F(ab’)2 reduced clinical scores, body weight loss and lung viral loads in mice treated 1 hour before virus exposure. Full
protection from disease was also observed when antibody was delivered up to 3 days prior to virus infection. Furthermore,
effective prophylaxis was independent of a strong innate immune response. This strategy presents a further option for
prophylactic intervention against influenza A virus using ruminants to generate a bulk supply that could potentially be used
in a pandemic setting, to slow virus transmission and reduce morbidity associated with a high cytokine phenotype.
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Introduction
A serious pandemic threat lies with a new emerging influenza A
virus that is highly virulent and transmissible and to which humans
have weak or no prior immunity [1,2,3,4]. Additionally, seasonal
influenza afflicts millions of people each year and is responsible for
over 250,000 annual deaths, despite available vaccination and
antiviral drugs [5]. Mortality rates for zoonotic avian influenza
viruses have reached 60% worldwide for H5N1 and approxi-
mately 30% for a newly emerged pathogenic H7N9 strain in
China [6,7]. The lag time required to produce and distribute
vaccines against influenza once a newly emergent virus strain has
been identified is likely to render many unprotected and at risk.
Indeed, during the last pandemic, the novel 2009 H1N1pdm swine
influenza virus was able to rapidly disseminate worldwide in six
weeks despite a record rate of manufacture of a strain-specific
vaccine, albeit with doses available to cover only 10% of the
world’s population. A new approach is needed, particularly one
supplementing those aspects where influenza control by vaccina-
tion is constrained, including the variable immunogenicity and
protracted time to develop full immunity post-vaccination in
individuals. Wide scale deployment of a prophylactic able to
provide immediate protection regardless of age and immune
memory, even if only temporarily, could dramatically reduce the
number of cases by preventing/reducing virus infection and
thereby have a significant impact on virus spread.
To augment the pandemic vaccination approach [8], adjunct
regimes of passive immunity mediated by antibodies specific for
influenza virus have been investigated [9,10,11]. Convalescent
human sera from survivors of the H1N1 Spanish Flu pandemic
have been effective in reducing the mortality rate but supply is not
readily available [12,13]. Although passive immunotherapies using
human monoclonal antibodies specific for viral HA and NA
subtypes and conserved M2 have demonstrated efficacy in
animals, equivalent to the antiviral drugs amantadine, oseltamivir
and zanamivir [14,15,16], their production and distribution
requirements would likely be impractical for emergency use and
potentially drive virus escape mutations, thereby limiting their
efficacy [17]. Polyclonal antibodies generated in ruminants by
vaccination with influenza A viruses have been shown to be
prophylactic in animal models of influenza with reduced lung virus
titres and increased survival upon virus challenge [18,19,20]. Most
often the delivery of antibody has been systemic via the
intraperitoneal or intravenous routes requiring large doses.
However, benefits of intranasal administration of antibodies are
dose sparing with targeting to the primary site of natural exposure
to influenza viruses. Topical delivery of antibodies to the
respiratory tract mucosa may also offer advantages of simple
self-administration by nasal spray. Moreover, production of
neutralizing antibodies against different influenza A virus groups
could be stockpiled for immediate use in controlling virus
outbreaks [21].
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Although intranasal delivery of influenza virus-specific antibod-
ies derived from bovine colostrum has been shown to provide
protection against influenza A virus infection, their influence on
host immune responses have not been reported [22]. Homeostasis
is paramount in the lung [23], however, during virus infection, the
rapid induction of innate cytokine responses, including the type I
interferons, are essential for effective influenza-specific immunity
[24,25]. Interferon-a/b have potent and direct antiviral properties
in addition to modulatory effects on immune responses but
hyperinduction of cytokines in the respiratory tract leads to acute
lung injury and acute respiratory distress syndrome in some
individuals, which can be fatal [26,27]. This was most evident in
the 1918 Spanish Flu pandemic, especially in healthy young adults
with a robust immune system [28]. A significant benefit would be
to provide antiviral immunity whilst protecting predisposed
individuals and those in age groups susceptible to severe illness
caused by such ‘‘cytokine storms’’ induced by their inflammatory
responses in exposure to lethal influenza A virus strains. In this
study, we have investigated the efficacy and influence on the
innate immune response of influenza-specific polyclonal antibod-
ies, raised in sheep, against influenza in a mouse model. We report
that a single topical administration of virus-specific polyclonal IgG
elicits complete protection when delivered up to 3 days before




Animal experimentation was compliant with the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purposes. All mouse (Mus musculus) experimentation was conducted
with approval from Murdoch University (R2229/09) and The
University of Western Australia (RA/3/100/89) Animal Ethics
Committees. All sheep (Ovis aries) experimentation was performed
with ethics approval from Murdoch University (R2178/08) and
conducted at the Murdoch University Veterinary Farm.
Influenza A Virus Antigen Preparations
Antigen preparations for immunization of sheep were prepared
from influenza A/Puerto Rico/8/34 (PR8) virus obtained from
ATCC and propagated in confluent Madin Darby Canine Kidney
(MDCK) cells grown in Dulbecco’s modified Eagle’s medium
(DMEM, Sigma, MO, USA) with 0.5% fetal calf serum (Gibco,
Aukland, NZ) and 5mg/mL trypsin, penicillin (100 U/mL) and
streptomycin (100mg/mL) (Sigma, MO, USA). Crude tissue
culture supernatant containing virus was inactivated with formalin
(Sigma, MO, USA) for 65 hrs at 37uC and clarification by
centrifugation at 5,2506 g for 5 min. Bulk tissue culture
supernatant containing virus was also concentrated using a
10 kDa membrane cut-off Amicon (Millipore, Cork, Ireland),
pelleted by centrifugation at 114,0006 g for 90 min at 4uC and
purified by sucrose gradient ultracentrifugation [29]. The purified
virus was then resuspended in 1 mL 0.05 M sodium acetate/
2 mM sodium chloride/0.2 mM EDTA (pH 7.0) and detergent-
disrupted by treatment with 0.01% Triton X-100 (Sigma, MO,
USA) overnight at 4uC and then diluted in PBS. Virus antigens
were prepared as water-in-oil emulsions with Titermax Gold
adjuvant (CytRx Corporation, GA, USA) and contained 0.3 mg
protein/mL per vaccine dose as determined by the Bradford
protein assay.
Ovine Serum and Whey Samples
Lactating ewes were immunized with either inactivated virus
antigen or purified detergent-disrupted virus antigen preparations
in the gluteal muscle mass of the hind leg, followed by a further
two boosters at day 14 and days 21–28. Blood and milk was
collected at days 45–58 from immunized sheep and non-
immunized sheep as a control. Both serum and whey were stored
at 220uC.
Antibody Purification
IgG purification from serum was performed using Protein-G
affinity chromatography, with PBS (pH 7.3) as running buffer and
0.1 M Glycine (pH 2–3) as elution buffer. Eluted protein fractions
were neutralized with 1 M Tris (pH 7.5–9) and then diafiltrated
with PBS using 10 kDa cut-off membranes. Protein was concen-
trated using 50 kDa cut-off Amicon ultrafiltration membrane and
endotoxins removed with Detoxi-GelTM columns (Thermo Scien-
tific, Rockford, USA). For F(ab’)2 preparation, purified IgG was
dialyzed against 0.2 M sodium acetate (pH4.5) for 4 hr at 4uC and
digested (1 mg/ml) with pepsin (0.1 mg/ml) for 24 h at 37uC,
after which the pH was increased to 8.0 with 2 M Tris base and
the resulting F(ab’)2 fragments dialysed against PBS overnight at
4uC. Purified IgG and pepsin digested IgG were characterized by
SDS-PAGE. Under reducing conditions, two major bands were
seen for IgG, representing H (50 kDa) and L (25 kDa) chains,
whereas the F(ab’)2 preparation showed L (25 kDa) chains only
(data not shown). Protein concentrations were determined by
absorbance at 595 nm wavelength by the Bradford method using
colorimetric protein assay (Bio-Rad, CA, USA) and spectropho-
tometry.
Hemagglutination Inhibition (HI) Assay
HI assays were performed according to standard protocols [30]
using receptor destroying enzyme, 4 hemaggluninating units
(HAU) of influenza PR8 virus and 1% chicken erythrocytes in
round-bottom microtitre plates (Falcon, USA). Titres were
expressed as the reciprocal of the highest dilution of antibody
sample that inhibited hemagglutination.
Neuraminidase Inhibition (NI) Assay
The NI assay was performed as previously described with a 1 hr
incubation of 25mL anti-serum and 25mL influenza PR8 virus at
room temperature prior to neuraminidase assay using fetuin and
periodate, arsenite and thiobarbituric acid reagents in 96-well
tissue culture plates [31,32].
Microneutralization (MN) Assay
Determination of virus neutralization titres of heat-inactivated
whey and serum samples was performed using standard protocols
and 102TCID50 influenza PR8 virus [33]. MDCK monolayers
were grown to confluency in DMEM and 10% FCS before
washing twice with PBS. Serially diluted antibody preparations
were mixed with an equal volume of virus and incubated for
60 mins at 37uC and 5%CO2. MDCK cells were then incubated
in duplicate, with 100mL of virus/antibody mixtures diluted in
DMEM with 0.5% FCS and 5mg/mL trypsin, for 72 hours at
37uC and 5%CO2. Cytopathic effect was scored and the MN titre
expressed as the reciprocal of the highest dilution with 100%
inhibition of cytopathic effect.
Hemagglutination (HA) Assay
The hemagglutination assay (HA) was performed using
standard protocols described by the World Health Organisation
Passive Antibody for Influenza
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[30]. Briefly, PR8 virus was serially diluted in PBS/0.1% FCS and
incubated with 1% chicken red blood cells in U-bottom shaped
microtitre plates at 4uC for 60 minutes. 1 HAU was defined as the
reciprocal of the last dilution to provide complete hemagglutina-
tion of the RBC.
Antibody ELISA
Mouse anti-sheep antibodies were determined by ELISA [34]
using sheep IgG (1mg/well, Abcam, Cambridge, MA, USA) to
coat plates overnight at 4uC. Plates were blocked with 1%
ovalbumin before addition of mouse serum samples (day 14 p.i.)
that were serially diluted in PBS-Tween 20. Antibody reactivity
was detected using conjugated anti-mouse IgG alkaline phospha-
tase and 4-nitrophenyl phosphate disodium salt hexahydrate
diluted with diethanolamine buffer as substrate. Absorbance was
read at 405 nm by spectrophotometry.
Treatment Protocol and Challenge Infection of Mice
Specific pathogen-free inbred BALB/c mice (6–10 weeks old)
were obtained from the Animal Resource Centre (Murdoch, WA,
Australia) and housed at the Animal House facility at Murdoch
University. Mice were lightly anaesthetized with methoxyfluorane
before infection with 25mL influenza PR8 virus (102TCID50) by
the intranasal route via administration by micropipette to the
nares. For antibody prophylaxis, mice were given 25mL antibody
or PBS by the intranasal route 1 hr, 1 day, 3 days or 7 days before
virus infection or 1 day after virus infection. Mice were killed by
lethal dose of sodium pentobarbitol 3 days after virus infection for
determination of virus titres in the lungs or monitored daily for
clinical symptoms (ranging from 0–5) and weight changes over 2
weeks p.i. Clinical scores were defined as 0) healthy, 1) barely
ruffled fur, 2) fur ruffled but active, 3) fur ruffled and inactive, 4)
fur ruffled, inactive and hunched appearance, and 5) dead. Mice
were culled if they had lost .25% body weight and reached a
clinical score of 4, due to ethical considerations. Mice were bled at
day 14 p.i. and serum stored at 220uC.
Lung Characterization
Virus loads in the lungs were determined by TCID50 assay using
lung homogenates (20%w/v) and MDCK cells. The log10 TCID50
titre was calculated according to the Reed and Muench method
[35]. Bronchioalveolar lavage (BAL) was performed using 0.5 mL
PBS with three washings for each animal. BAL fluid samples were
centrifuged at 4506g for 10 mins and the supernatant stored at 2
80uC.
Cytokine Assays
Type I interferons in the BAL fluid samples were quantitated in
the bioassay as previously described [36] using 70% confluent
L929 cells grown in DMEM and 10% FCS at 37uC and 5%CO2.
Cells were washed twice in PBS and then the IFN standard
(Universal IFN, PBL Interferon Source, NJ, USA) or samples
serially diluted in DMEM and 1% FCS were added in duplicate to
the cells and incubated overnight at 37uC and 5%CO2. Following
a further 24 hr incubation with encephalomyocarditis virus, a
reduction in cytopathic effect (CPE) was indicative of antiviral
activity and endpoint titres determined by the highest dilution
resulting in 50% reduction of CPE.
Flow cytometry was used to determine IFN-c, IL-1b, TNF-a,
IL-6 and CXCL1 levels in the BAL fluid samples by cytokine bead
array according to manufacturer’s instructions (BD, MD, USA).
Fluorescence was measured using the FACSCanto II and
FACSDiva V6.1.2 (BD Biosciences) software. Data was analyzed
using FCAP Array V3.0 software based on 5 parameter logistic
curve fits.
Statistical Analysis
Statistical analyses were performed using ANOVA with Tukey’s
multiple comparison test (Prism V5 GraphPad Software Inc., CA.
USA). P values ,0.05 were considered significant and are shown
for comparisons of treatment groups with PBS controls unless
stated otherwise.
Results
Immunogenicity of whole inactivated and split influenza
PR8 virus vaccines in sheep
Advantages of tissue culture-based vaccines are that most
influenza A virus strains grow well in cell culture without the need
for extensive reassortment, which is required to produce seed
viruses, and have a shorter scale-up period than egg-based systems
[37,38]. As different vaccine formulations can vary in efficacy
according to species, we evaluated the immunogenicity of several
PR8 H1N1 virus vaccine types prepared using cell culture systems
on antibody production in sheep. Sheep were chosen as a suitable
alternative ruminant to more expensive and larger cattle while
allowing proof-of-concept studies in influenza prophylaxis using a
mouse model. Thus in order to evaluate the immunogenicity of
different virus antigen preparations, we examined the effect of
whole inactivated virus and detergent-disrupted (split) virus on the
induction of a virus-specific antibody response in sheep. A number
of mechanisms including binding to HA and NA are required for
neutralization of influenza A viruses [39]. For this reason we used
HI, NI and MN assays to determine ovine antibody specificity to
influenza PR8 virus. HI and MN antibody titres in serum and
whey samples were generally higher in response to split virus
antigen than the inactivated virus antigen (Table 1), likely
dependent on HA protein concentrations. Only the split virus
induced antibodies in the sera with positive NI activity to
homologous PR8 virus, possibly due to higher concentrations of
the NA antigen component in the purified preparation.
Table 1. Antibody titres to influenza A/PR/8/34 (H1N1) in
sheep immunized with either whole inactivated or split PR8
virus.
Virusa Sample HIb MNc NId
Inactivated
virus
Serum 20, 320, 80 40, 640, 80 -, -, -
Whey ,10, 10, 10 ,10, ,10, ,10 ND
Split virus Serum 640, 80 12800, 6400 +, +
Whey 160, ,10 12800, 100 ND
aSheep were immunized with inactivated whole influenza A PR8/34 virus (n = 3)
or purified split PR8 virus (n = 2) with adjuvant (Titermax Gold) at weeks 0, 2 and
3–4 and samples collected at weeks 6 and 8, respectively.
bH1-specific antibody titres in sera and whey determined by HI assay using
homologous virus as antigen. Data expressed as reciprocal endpoint dilution of
sample from individual sheep.
cMicroneutralization titres in sera and whey determined by microneutralization
assay using homologous virus. Data expressed as reciprocal endpoint dilution
of sample from individual sheep.
dN1-specific antibody reactivity in sera determined by NI assay using
homologous virus as antigen and expressed as (+) positive or (-) negative for
individual sheep.
doi:10.1371/journal.pone.0089674.t001
Passive Antibody for Influenza
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Virus neutralization by PR8-specific ovine IgG in vitro
A number of antibody isotypes are found in the humoral
response to influenza virus infection, but IgG plays a predominant
role in virus neutralization [40,41]. To evaluate the contribution of
ovine IgG in neutralization of virus, IgG was purified using protein
G affinity chromatography. Purified IgG from the split virus-
immunized sheep was found to have a higher MN titre (6400) than
the serum from the inactivated virus immunized sheep (320),
however both purified IgG preparations had a reduced MN titre
than whole serum preparations, likely due to some loss during the
column chromatography process.
Prophylactic efficacy of PR8-specific ovine IgG
Antibody responses to influenza virus are important correlates
of protection against influenza infection in vivo. Since, prophylactic
use of heterologous antibody to provide passive immunity in a
different species to that of the antibody source has been successful,
we evaluated the effect of ovine antibody on influenza virus
replication in the mouse model. We compared the effects of
intranasal instillation of neutralizing virus-specific sheep IgG with
PBS as a control, on protection of mice challenged by the same
intranasal route with a sublethal dose of H1N1 influenza PR8
virus. The antibody dose of 125mg was chosen because it was
known to prevent replication of 102TCID50 influenza PR8 virus in
vitro as determined by the MN assay. Clinical scores and body
weight loss were examined daily during the first 2 weeks post-viral
challenge. PBS treatment did not significantly reduce weight loss
and clinical illness following virus challenge (Figure 1). In contrast,
neutralizing virus-specific IgG preparations elicited reduced
weight loss and lower clinical scores, even when delivered up to
3 days before virus challenge but was not effective when applied at
7 days before or 1 day after virus exposure.
Since topical delivery of virus-specific antibody to the mucosal
surface of the respiratory tract is a relevant site for protection from
exposure to replicating virus, we next examined the ability of
antibody treatment to reduce lung viral loads at day 3, a time of
peak virus replication. Both the neutralizing IgG and F(ab’)2
preparations derived from the split virus immunized sheep
significantly reduced lung viral loads in challenged mice when
antibody was administered 1 hour before virus challenge in
contrast to high viral loads in the lungs of PBS and non-specific
F(ab’)2 treated animals (Figure 2a). Partial protection was observed
in animals treated with non-specific IgG, similar to that previously
reported for bovine IgG [22]. Furthermore, clearance of virus
Figure 1. Protection of mice against influenza H1N1 virus with
ovine IgG antibodies. Lightly anaesthetized female BALB/c mice
(n = 10) were given 125mg IgG from split virus-immunized sheep or PBS
by the intranasal route one hour, 1 day, 3 days, 7 days before or 1 day
after i.n. challenge with 102TCID50 PR8 and monitored daily for clinical
illness and body weight loss. (a) Clinical score and (b) percentage
weight change data are representative of four separate experiments
with mean 6 SEM shown. *P#0.05, **P#0.01, ***P#0.001 represent
comparisons between antibody-treated (-1 hr) and PBS control groups.
doi:10.1371/journal.pone.0089674.g001
Figure 2. Lung viral titres in ovine IgG protected mice. Lightly anaesthetized female BALB/c mice (n = 5–16) were given (a) 125mg IgG or F(ab’)2
from split virus-immunized sheep, PBS or non-specific IgG or F(ab’)2 by the intranasal route one hour before i.n. challenge with 10
2TCID50 PR8. (b)
Mice were similarly given 125mg IgG from split virus-immunized sheep 1 day, 3 days, 7 days before or 1 day after virus challenge. Lung viral loads at
day 3 p.i. were quantitated by TCID50 assay and individual titres and mean 6 SEM are shown. Results are representative of four separate experiments
and the dashed line shows the limit of detection. ** P#0.01, ***P#0.001 represent comparisons between antibody-treated and PBS control groups.
doi:10.1371/journal.pone.0089674.g002
Passive Antibody for Influenza
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infection was evident in most of the mice given influenza specific-
IgG at 3 days and 1 day before but not at 7 days before or 1 day
after virus challenge (Figure 2b). Therefore, prophylaxis with
topical administration of neutralizing IgG antibodies up to 3 days
before virus exposure can effectively control influenza.
Prevention of interferon responses in PR8-specific ovine
IgG-protected mice
Although high neutralizing IgG from sheep was shown to
neutralize PR8 virus in vitro and prevent virus replication in vivo, the
IgG-neutralized virus may be able to stimulate host innate
immune responses that rapidly clear the virus. Recognition of
foreign antigens through PAMP molecular encounters can lead to
the early induction of innate interferon responses, which have
potent antiviral properties [42,43,44]. We investigated contribu-
tion of the interferon-a response to the reduction of lung viral
loads at day 3 p.i. in antibody-protected mice. Although a strong
type I interferon response was found in the BAL samples taken at
day 3 p.i. of most of the PBS-treated animals and mice given
influenza non-specific IgG or F(ab’)2, complete abrogation of the
type I IFN response was observed in animals given 125mg of the
neutralizing IgG or (Fab’)2 derived from the split virus immunized
sheep one hour before virus challenge (Figure 3a). The timing of
antibody prophylaxis relative to virus challenge influenced the
induction of a type I IFN response in the mice (Figure 3b).
Reduced mean titres of IFN-a were found at day 3 p.i. of mice
treated with high neutralizing antibody at 7 and 3 days before
virus infection, despite some animals showing virus replication.
However, some animals showed a type I IFN response in the BAL
fluid samples when given virus-specific IgG one day after virus
infection. Taken together, these results suggest that pre-exposure
antibody treatment has potential value in neutralizing virus and
clearing the infection during the acute stages, largely without a
strong type I IFN response.
Type II IFN levels during influenza virus infection largely
indicate T cell activation and can be utilized as a biomarker for
cell-mediated immune responses [45]. IFN-c was measured by
flow cytometry in the BAL fluid samples taken at day 3 p.i. Mice
treated with neutralizing IgG derived from the split virus
immunized sheep at one hour before virus exposure had no
detectable IFN-c levels (Figure 4). Only one animal in each group
given virus-specific IgG treatment 3 and 7 days prior to virus
challenge produced an IFN-c response, whereas 3/4 animals in
the group treated 1 day post-virus challenge, mounted a type II
IFN response. In contrast to untreated animals, the cytokines IL-
1b, TNF-a and IL-6 were not detected in BAL fluid samples at
day 3 post-virus challenge of all animals pretreated with
neutralizing IgG one hour before virus exposure (Fig. 4). In
addition, TNF-a levels were significantly reduced when IgG was
given either 7 or 3 days before virus challenge. The trend of lower
IL-1b IL-6, IL-12 and CXCL1 (KC) levels was also observed in
mice given antibody prophylactically, although not reaching
significance. However, antibody delivered 1 day after virus
exposure did not significantly change the cytokine levels for IL-
1b, TNF-a, IL-6, IL-12 or CXCL1 in these unprotected mice.
Host antibody responses to PR8 and sheep Ig
As antibody responses to influenza virus are commonly used as
a correlate of protection in most species, we examined the effects
of prophylaxis on the development of endogenous antibody
responses to virus in mice using serum collected 14 days p.i. A
strong antiviral antibody response was observed in the virus-
infected PBS control mice (Figure 5a). However, circulating
antibodies had markedly reduced MN titres in mice given
neutralizing antibody one hour before virus challenge, suggesting
immediate virus neutralization. No significant changes in antibody
levels were seen for mice treated with ovine IgG 1 day, 3 days or 7
days before and 1 day after virus exposure, indicating that these
mice were virus-infected. Since xenogeneic protein can also
stimulate B cell antibody production [46], we evaluated the
humoral immune response to sheep Ig in mice (Figure 5b). Despite
no signs of adverse reactions, an anti-ovine antibody response was
generated in all mice given ovine polyclonal IgG by the i.n. route.
As expected, there was no evidence of antibody reactivity to sheep
Ig in the PBS-treated and virus-infected control mice that were not
pretreated with ovine antibodies.
Figure 3. Interferon-a responses in the BAL samples of ovine
IgG treated mice. Lightly anaesthetized female BALB/c mice (n = 5)
were given (a) 125mg IgG or F(ab’)2 from split virus-immunized sheep,
PBS or non-influenza specific control IgG or F(ab’)2 by the intranasal
route one hour before i.n. challenge with 102TCID50 PR8. (b) Mice were
similarly given 125mg IgG from split virus-immunized sheep at 3 days
before, 7 days before or 1 day after virus challenge. PBS was given one
hour before virus infection. Results are representative of two separate
experiments. Interferon-a responses in the BAL fluid samples collected
at day 3 p.i. were quantitated by bioassay and individual titres and
mean 6 SEM are shown. The dashed line shows limit of detection.
doi:10.1371/journal.pone.0089674.g003
Passive Antibody for Influenza
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Discussion
In this study our objective was to evaluate the efficacy of passive
immunization with antibody on influenza prophylaxis using a
ruminant source of polyclonal IgG antibodies. Virus infection
stimulates innate immune responses that promote clearance of
influenza virus infections, but these responses can also contribute
to inflammation and pulmonary pathology [25,26]. Although
passive immunization with ruminant antibody has been shown to
be effective against influenza [47], little is known of its influence on
the host innate immune response. Since hyper-induction of innate
cytokines leads to acute respiratory distress, knowledge of the
effects of passive antibody for influenza prophylaxis on cytokine
induction is essential [48]. Here we generated polyclonal
antibodies against influenza A/PR8/34 (H1N1) virus in sheep,
which were then administered by the intranasal route to mice
followed by intranasal challenge with homologous virus. We
observed significant reduction of body weight loss, clinical signs
Figure 4. Cytokine responses in the BAL samples of ovine IgG protected mice. Lightly anaesthetized female BALB/c mice (n = 4) were given
125mg IgG from split virus-immunized sheep or PBS by the intranasal route one hour, 1 day, 3 days, 7 days before or 1 day after i.n. challenge with
102TCID50 PR8. Cytokines measured by flow cytometry using cytokine bead arrays for IL1-b, TNF-a, IL-6, IL-12, IFN-c and KC (CXCL1). Results are
representative of four separate experiments with individual titres and the mean 6 SEM shown. **P#0.01, ***P#0.001 represent comparisons
between antibody-treated and PBS control groups. The bar with asterisks denotes significance levels between the specified (+1 day and -1 hr)
antibody-treated groups.
doi:10.1371/journal.pone.0089674.g004
Passive Antibody for Influenza
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and lung viral loads and identified that the ruminant polyclonal
IgG antibodies were efficacious without induction of the host
innate immune response. Thus passive immunization with
ruminant polyclonal antibodies represents an additional therapeu-
tic to the arsenal against influenza.
Whole inactivated virus was previously identified as an
inexpensive and potent immunogen in animals and is used
routinely to vaccinate many species, including poultry against
avian influenza viruses [49,50]. Split virus vaccines are currently
used for immunization to target the viral surface glycoproteins HA
and NA [51,52]. We tested the immunogenicity of these influenza
viral antigen preparations in sheep to generate circulating
antibodies. Although both viral antigen preparations induced
ovine antibody responses, the split virus antigen was more
immunogenic in sheep, largely eliciting more neutralizing
antibodies in the serum and whey as determined by the MN, HI
and NI assays, possibly due to increased viral H and N proteins.
In our study, ovine influenza-specific IgG was superior to PBS
at reducing clinical, scores, weight loss and lung viral loads in mice
when given prophylactically up to 3 days before virus exposure.
We also observed normal lung architecture in mice protected with
ovine antibody pre-treatment with ablation of the neutrophil
infiltrate in the airways at day 3 [data not shown], an immune
response shown to predict gene signatures in lethal influenza with
immune-related pathology [53,54]. Intranasal delivery of bovine
IgG was previously identified as being prophylactic for influenza in
mice, when both specificity of antibodies and challenge virus were
strain matched and administered by the i.n. route [22]. However,
these colostrum-derived antibodies are only produced for a short
period of time immediately after calving. The continuous supply of
antibodies produced in the milk of dairy animals provides a
potential bulk source of antibody. Furthermore, antibodies
delivered directly to the upper respiratory tract allows both virus
neutralization and clearance of virus infection. Antibodies instilled
in the nares of lightly anaesthetized mice must be able to protect
the upper respiratory tract from invading virus, and possibly gain
entrance to the lungs to guard against lower respiratory tract
infection. The mucosal route of delivery also minimizes the risk of
host allergic-type reactivity to foreign proteins as it is systemically
non-invasive. We have found previously, that repeated intranasal
administration of ovine IgG to mice daily for 6 days does not
induce adverse side effects, despite a neutrophil response in the
lungs [data not shown]. However, it will be important to further
assess the immunogenicity and safety of ruminant antibodies. Also
the efficacy of i.n. delivery of antibodies in protecting animals
against exposure to an aerosolized virus warrants future studies in
order to reflect natural influenza A virus transmission.
Although the protective effect of ovine IgG was complete when
a single dose of 125mg IgG was given one hour before virus
challenge, this likely indicates immediate virus neutralization in
the nasal passages as a strong endogenous antiviral antibody
response was prevented. In contrast, control mice receiving PBS
treatment 1 hour before virus challenge showed severe clinical
illness, lost significant weight, and developed an antiviral antibody
response to virus infection. To test the robustness of passive
immunity we also examined the influence of timing on protective
efficacy of ovine virus-specific IgG for influenza. Protective effects
were demonstrated with 125mg IgG delivered to mice at 1 day and
3 days prior to virus infection. As such mice also produced an
influenza-specific IgG antibody response, evident by ELISA using
day 14 immune sera, this result suggests that the protective ovine
antibodies were capable of clearing an acute virus infection in the
respiratory tract. However, therapeutic use of IgG even 1 day after
virus infection did not reduce viral load in the lungs or lessen
clinical disease symptoms. This was an unexpected finding as
others have reported therapeutic efficacy of antibodies, although
protection was reduced with times beyond 24 hours after virus
infection [55]. Higher doses of antibody with increased neutral-
ization capacity may overcome this problem as has been observed
in other reports of antibody therapy [56]. Further studies to
elucidate the protective efficacy of ovine antibodies against lethal
influenza virus doses would provide data on mortality rates.
For the first time passive immunization with ovine antibody was
examined in mice for modulation of the innate cytokine response
in the lung to respiratory virus infection. Type I IFNs and pro-
inflammatory cytokines IL-1b, TNF-a, IL-6, and CXCL1 were
shown to be rapidly induced by virus in PBS-treated control
animals, whereas in antibody-protected animals their levels were
mostly reduced. These results indicate that the protective effects
mediated by passively acquired antibody before virus exposure
influence the host’s innate cytokine responses.
Acute respiratory infections are responsible for nearly 4 million
deaths every year, mostly of children and infants in developing
countries [57]. There is a real threat that a pandemic caused by
influenza could occur at anytime with dire consequences. Current
Figure 5. Antibody responses to ovine IgG and virus in ovine
IgG protected mice. Lightly anaesthetized female BALB/c mice (n = 5)
were given 125mg IgG from split virus-immunized sheep or PBS by the
intranasal route one hour, 1 day, 3 days, 7 days before or 1 day after i.n.
challenge with 102TCID50 PR8. Endpoint antibody titres in the serum
collected at day 14 p.i. were measured by (a) MN assay for reactivity to
homologous PR8 virus and (b) ELISA for reactivity to sheep IgG. Results
are representative of two separate experiments with individual titres
and the mean 6 SEM shown. ***P#0.001 represent comparisons
between antibody-treated and PBS control groups.
doi:10.1371/journal.pone.0089674.g005
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control methods of vaccination for prevention of influenza virus
infection and antiviral drugs for treatment of influenza are not
ideal in a pandemic situation due to high manufacturing costs,
delays in production and emerging resistance to antivirals.
Therefore, adjunct options for control of influenza need to be
developed. Use of convalescent sera from people recovered from
H1N1 influenza in the 1918 pandemic was successful during a
period when antivirals and antibiotics were not available [12].
Also, convalescent plasma was used to effectively treat H5N1
infected individuals in China [58]. Since the supply of human
immune sera is scarce, particularly during a pandemic, an
alternative supply is required. We propose the generation of
anti-influenza virus polyclonal antibodies in ruminants. Such a
strategy has several benefits over challenges of vaccination with
strain-matching requiring updated formulations of virus antigens
and the protracted time of several weeks to develop full immunity
post-immunization. This approach represents a barricade control
measure for influenza that could be prepared in advance and
stockpiled for use during the intervening period between
identification of a new virus strain and availability of a vaccine
for influenza epidemics and pandemics. Here we provide proof-of-
concept for use of ruminant antibodies. Our mouse studies clearly
establish that ovine anti-PR8 antibodies can prevent and/or clear
influenza infection. Polyclonal antibody preparations are associ-
ated with lower cost, rapid production times and suitability for low
resource settings, making them ideal for use in regions likely to
experience virus outbreaks during the crisis period of an influenza
pandemic. Further development of ruminant antibodies with
broad neutralizing capacity and evaluation in challenge studies
with heterologous influenza virus strains are required to reveal
their full potential.
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